| YAP oncogene overexpression supercharges colon cancer proliferation. | colorectal, |
| Our findings suggested that Yes-associated protein contributes to primary liver tumorigenesis and likely mediates its oncogenic effects through modulating Survivin expression. | liver, |
| crosstalk between the insulin/IGF signaling pathway and Yorkie leads to coordinated regulation of these two oncogenic pathways in hepatocellular carcinoma | liver, |
| these findings suggest that in meningiomas, deregulation of the Hippo pathway is largely observed in primary tumors and that YAP1 functions as an oncogene promoting meningioma tumorigenesis. | meningiomas, |
| Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. | meningiomas, |
| YAP1 has oncogenic potential in cervical cancer with distinct functions in squamous cell carcinomas and adenocarcinoma. | cervical, |
| Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. | lung, |
| microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. | endometrial, |
| Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. | pancreatic, |
| Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. | endometrial, |
| YAP1 is a potent embryonal rhabdomyosarcoma oncogenic driver. | sarcoma, |
| Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. | colorectal, |
| The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. | bladder, |
| FOXM1 is regulated by LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer | ovarian, |
| Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma. | sarcoma, |
| YAP may act as an oncogene and predict poorer prognosis in well differentiated lung adenocarcinoma. | lung, |
| these results provide genetic evidence of YAP/TAZ as oncogenic initiators and drivers for gastric tumors with MYC as the key downstream mediator. | gastric, |
| the oncogenic cooperation between YAP and mutant p53 may translate into better survival outcomes in advanced gastric cancer | gastric, |
| By elucidating a novel SUMOylation-mediated control mechanism of YAP/TAZ signaling in breast cancer metastasis, we have revealed previously unknown interplay between oncogenic KRAS and EGFR signaling and YAP/TAZ protein stability | breast, |
| HBO1 preferentially acetylates histone H4 through the concomitant overexpression of co-regulator JADE2, and is required for the expression of YAP1, an ovarian cancer oncogene and mechano-transductor signaling factor. | ovarian, |